These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 16115948)

  • 1. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.
    Takao M; Okamoto A; Nikaido T; Urashima M; Takakura S; Saito M; Saito M; Okamoto S; Takikawa O; Sasaki H; Yasuda M; Ochiai K; Tanaka T
    Oncol Rep; 2007 Jun; 17(6):1333-9. PubMed ID: 17487387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
    Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
    Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].
    Konno R
    Hum Cell; 2001 Dec; 14(4):261-6. PubMed ID: 11925926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
    Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
    Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer.
    Sawiris GP; Sherman-Baust CA; Becker KG; Cheadle C; Teichberg D; Morin PJ
    Cancer Res; 2002 May; 62(10):2923-8. PubMed ID: 12019173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
    Marquez RT; Baggerly KA; Patterson AP; Liu J; Broaddus R; Frumovitz M; Atkinson EN; Smith DI; Hartmann L; Fishman D; Berchuck A; Whitaker R; Gershenson DM; Mills GB; Bast RC; Lu KH
    Clin Cancer Res; 2005 Sep; 11(17):6116-26. PubMed ID: 16144910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray.
    Sakamoto M; Kondo A; Kawasaki K; Goto T; Sakamoto H; Miyake K; Koyamatsu Y; Akiya T; Iwabuchi H; Muroya T; Ochiai K; Tanaka T; Kikuchi Y; Tenjin Y
    Hum Cell; 2001 Dec; 14(4):305-15. PubMed ID: 11925933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.
    Brandacher G; Perathoner A; Ladurner R; Schneeberger S; Obrist P; Winkler C; Werner ER; Werner-Felmayer G; Weiss HG; Göbel G; Margreiter R; Königsrainer A; Fuchs D; Amberger A
    Clin Cancer Res; 2006 Feb; 12(4):1144-51. PubMed ID: 16489067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
    Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
    Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
    Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV
    Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
    Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
    Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
    Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
    Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
    Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
    Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
    Lu KH; Patterson AP; Wang L; Marquez RT; Atkinson EN; Baggerly KA; Ramoth LR; Rosen DG; Liu J; Hellstrom I; Smith D; Hartmann L; Fishman D; Berchuck A; Schmandt R; Whitaker R; Gershenson DM; Mills GB; Bast RC
    Clin Cancer Res; 2004 May; 10(10):3291-300. PubMed ID: 15161682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for genes associated with ovarian cancer prognosis.
    Chang XH; Zhang L; Yang R; Feng J; Cheng YX; Cheng HY; Ye X; Fu TY; Cui H
    Chin Med J (Engl); 2009 May; 122(10):1167-72. PubMed ID: 19493465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.